Soocheol Jeong

Hiroshima University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Hiroto Ishihara

Jikei University School of Medicine

Kazuaki Chayama

Hiroshima University

Hiroiku Kawakami

Kawamura Hospital

Hiroshi Aikata

Hiroshima University

Mikiya Kitamoto

Hiroshima Prefectural Hospital

Shiomi Aimitsu

Hiroshima General Hospital

Yoshiiku Kawakami

Hiroshima University

Shoichi Takahashi

Star General Hospital

Shintaro Takaki

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

Michio Imamura

Hiroshima University

Cooperative Institutions

Hiroshima University

RIKEN Center for Integrative Medical Sciences

Hiroshima University Hospital

RIKEN

Life Science Institute

Frontier Science Foundation

The Japanese Society of Gastroenterological Surgery

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

Japanese Red Cross Hiroshima College of Nursing

Frontier Medical College

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Prospective study of short‐term peginterferon‐α‐2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy

Journal of Gastroenterology and Hepatology (2008)

Soocheol Jeong Yoshiiku Kawakami Mikiya Kitamoto Hiroto Ishihara Keiji Tsuji

Abstract Background and Aims: Long‐term interferon (IFN) therapy is effective in eliminating hepatitis C virus (HCV). However, it carries the risk of adverse effects and reduced quality of life. To assess whether short‐term IFN therapy effectively eliminates HCV, we performed a prospective pilot study of pegylated (peg)IFN‐α‐2a therapy for 8 or 24 weeks. Methods: After excluding patients with high titers of genotype‐1, 55 HCV patients received pegIFN‐α‐2a. Patients who became negative for HCV‐RNA at week 2 were allocated to either an 8‐week ( n = 19) or 24‐week ( n = 15) course of IFN. We evaluated the efficacy of and tolerance to IFN therapy. Results: The sustained virological response rate was excellent in the two groups (8 weeks, 89.5% [17/19]; 24 weeks, 100% [15/15], respectively,). IFN dose reduction was required in one patient of the 8‐week group, but in six patients of the 24‐week group ( P = 0.028). Treatment was completed by all patients of the 8‐week group, but discontinued in five patients of the 24‐week group ( P = 0.011). Conclusions: The 8‐week IFN therapy is more tolerable than the 24‐week therapy and had similar outcomes. Excluding the patients with high titers of genotype‐1, we recommend switching to an 8‐week course of pegIFN‐α monotherapy once patients show an ultra rapid virological response at week 2 from the start of IFN therapy.

Combination therapy

Pegylated interferon

10.1111/j.1440-1746.2008.05356.x

Cite

Citations (7)

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma

World Journal of Gastroenterology (2007)

Soocheol Jeong

AIM:To assess the efficacy of low-dose intermittent interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related compensated cirrhosis who had received curative treatment for primary hepatocellular carcinoma (HCC). METHODS:We performed a prospective case controlled study.Sixteen patients received 3 MIU of natural IFNalpha intramuscularly 3 times weekly for at least 48 wk (IFN group).They were compared with 16 matched historical controls (non-IFN group). RESULTS:The cumulative rate of first recurrence of HCC was not significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 68.6% vs 80% at 1-and 3-year, P = 0.157, respectively).The cumulative rate of second recurrence was not also significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 35.9% vs 67% at 1-and 3-year, P = 0.056, respectively).Although the difference in the Child-Pugh classification score between the groups at initial treatment of HCC was not significant, the score was significantly worse at the time of data analysis in the non-IFN group than IFN group (7.19 ± 1.42 vs 5.81 ± 0.75, P = 0.0008).The cumulative rate of deviation from objects of any treatment for recurrent HCC was also higher in the non-IFN group than IFN group (6.7% and 27% vs 0 and 0% at 1-and 3-year, P = 0.048, respectively). CONCLUSION:Low-dose intermittent IFN-alpha therapy for patients with HCV-related compensated cirrhosis after curative HCC treatment was effective by making patients tolerant to medical or surgical treatment for recurrent HCC in the later period of observation.

Hepatitis C

10.3748/wjg.v13.i39.5188

Cite

Citations (29)